论文部分内容阅读
目的探讨恩替卡韦治疗HBeAg阳性慢性重度乙型肝炎的临床效果。方法选取周口市专科病医院2011年7月至2012年8月收治的56例HBeAg阳性慢性重度乙型肝炎患者为研究对象,给予恩替卡韦进行治疗,1年后观察其治疗效果及不良反应发生情况。结果治疗1年后,56例HBeAg阳性慢性重度乙型肝炎患者中丙氨酸氨基转移酶恢复正常46例,天门冬氨酸氨基转移酶恢复正常40例;血清学乙型肝炎病毒DNA转阴35例,HBeAg转阴10例,HBeAg血清学转阴8例。未发现较明显的严重不良反应。结论恩替卡韦治疗HBeAg阳性慢性重度乙型肝炎临床效果显著,安全性较高,患者产生的不良反应较不明显,具有较高的临床应用价值。
Objective To investigate the clinical efficacy of entecavir in the treatment of HBeAg-positive chronic severe hepatitis B Methods 56 cases of HBeAg-positive chronic severe hepatitis B patients who were treated in Zhoukou Specialized Hospital from July 2011 to August 2012 were enrolled in the study. After 1 year, their therapeutic effects and adverse reactions were observed. Results One year after treatment, 46 cases of alanine aminotransferase returned to normal in 56 cases of HBeAg-positive chronic severe hepatitis B, 40 cases of normal aspartate aminotransferase returned to normal, seronegative hepatitis B virus DNA negative 35 Cases, HBeAg negative in 10 cases, HBeAg seroconversion in 8 cases. No obvious serious adverse reaction was found. Conclusion The entecavir treatment of HBeAg-positive chronic severe hepatitis B has significant clinical effect, high safety and less adverse reactions in patients with high clinical value.